

ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS: GLOBAL MARKETS



PHM062B
May 2013

Yogita Zutshi
Project Analyst

ISBN: 1-56965-399-2

bcc | Research
Market Forecasting

BCC Research
49 Walnut Park, Building 2
Wellesley, MA 02481
866-285-7215, 781-489-7301
www.bccresearch.com
Custom Reports:
carol.laverty@bccresearch.com

TABLE OF CONTENTS

TOPIC	PAGE NO.
CHAPTER 1 INTRODUCTION	2
STUDY GOALS AND OBJECTIVES	2
REASONS FOR DOING THIS STUDY	2
SCOPE OF REPORT	2
INTENDED AUDIENCE	2
METHODOLOGY	2
INFORMATION SOURCES	3
ANALYST CREDENTIALS	3
RELATED BCC REPORTS	3
BCC ONLINE SERVICES	3
DISCLAIMER	4
CHAPTER 2 SUMMARY	6
SUMMARY	6
<i>SUMMARY TABLE GLOBAL MARKET FOR ALZHEIMER'S DISEASE, THROUGH 2017 (\$ MILLIONS)</i>	6
<i>SUMMARY FIGURE GLOBAL MARKET FOR ALZHEIMER'S DISEASE, 2011-2017 (\$ MILLIONS)</i>	7
FORECAST SUMMARY	7
DRIVERS FOR THE ALZHEIMER'S DISEASE MARKET	8
BARRIERS FOR THE ALZHEIMER'S DISEASE MARKET	8
CHAPTER 3 OVERVIEW	10
DEFINITION AND MARKET STRUCTURE	10
WHAT IS ALZHEIMER'S DISEASE?	10
<i>TABLE 1 U.S. ALZHEIMER'S PATIENTS, 2002-2050 (MILLIONS)</i>	10
<i>FIGURE 1 U.S. ALZHEIMER'S PATIENTS, 2002-2050 (MILLIONS)</i>	10
Role of the Cholinergic System	11
Role of Beta-Amyloid Protein	11
Behavioral Manifestations of AD	12
INCIDENCE AND PREVALENCE	13
<i>TABLE 2 POPULATION BY SELECTED GEOGRAPHIC REGION, 2011-2050 (MILLIONS)</i>	13
<i>TABLE 3 PERCENT POPULATION OVER 65 BY REGION, 2011 (%)</i>	13
<i>TABLE 4 PEOPLE WITH ALZHEIMER'S DISEASE BY AGE GROUP, 2004-2050 (MILLIONS)</i>	14
<i>FIGURE 2 PEOPLE WITH ALZHEIMER'S DISEASE BY AGE GROUP 2004-2050</i>	14
<i>TABLE 5 PERCENTAGE OF PEOPLE WITH ALZHEIMER'S, BY AGE BRACKET, 60-94 (%)</i>	14
<i>FIGURE 3 PERCENTAGE OF PEOPLE WITH ALZHEIMER'S, BY AGE BRACKET, 60-94 (%)</i>	14
<i>TABLE 6 GLOBAL DISEASE PREVALENCE: ALZHEIMER'S DISEASE (%)</i>	15
STAGES OF ALZHEIMER'S DISEASE	15
The Seven Stages	16
No Cognitive Decline	16
Very Mild Cognitive Decline (Occasionally Referred to as Mild Cognitive Impairment)	16
Mild Cognitive Decline (Early Confused Stage): Losses or Changes in the Ability to:	16

TOPIC	PAGE NO.
Moderate Cognitive Decline (Late Confusional Stage):	16
Moderately Severe Cognitive Decline (Early Dementia Phase):	17
Severe Cognitive Decline (Dementia):	17
Very Severe Cognitive Decline (Late Dementia or End Stage):	17
DIAGNOSIS	18
<i>TABLE 7 DIAGNOSTIC TESTS</i>	18
Exit 25 (Executive Interview)	19
Clock Drawing Test (CDT)	19
Urinalysis	19
Dipsticks Used in Urinalysis	20
Functional Assessment Staging Test (Fast)	20
EP-AD	20
How Accurate are the Screening Tests?	20
KEY EVENTS	22
PATENT EXPIRATIONS	22
NEW PRODUCT LAUNCHES	22
PRICING	22
KEY MARKETS	22
<i>TABLE 8 GLOBAL MARKET FOR ALZHEIMER'S DISEASE BY REGION, THROUGH 2017 (\$ MILLIONS)</i>	23
<i>FIGURE 4 GLOBAL MARKET FOR ALZHEIMER'S DISEASE, BY REGION, 2011-2017 (\$ MILLIONS)</i>	23
MARKET SIZE AND KEY PLAYERS	23
Therapeutics	24
<i>TABLE 9 EXISTING TREATMENTS FOR ALZHEIMER'S DISEASE</i>	24
<i>TABLE 10 GLOBAL EXISTING MARKET FOR SYMPTOM-ADDRESSING ALZHEIMER'S DISEASE BY TYPE, 2010-2017 (\$ MILLIONS)</i>	25
<i>TABLE 11 ESTIMATED GLOBAL MARKET FOR ALZHEIMER'S DRUG CLASSES BY GEOGRAPHICAL REGION (U.S., EUROPE, JAPAN, OTHERS), 2012 (\$ MILLIONS)</i>	25
<i>TABLE 12 TYPES OF DRUGS USED TO TREAT ALZHEIMER'S DISEASE</i>	26
<i>TABLE 13 MARKET SHARE OF EXISTING THERAPEUTICS FOR ALZHEIMER'S DISEASE, 2011 (%)</i>	26
<i>TABLE 14 BREAKDOWN OF TREATMENT MARKET BY DISEASE SEVERITY (%)</i>	27
<i>TABLE 15 DEMENTIA RATE BY UNDERLYING DISEASE (%)</i>	27
<i>TABLE 16 PERCENT OF PATIENTS WITH DEMENTIA/COGNITIVE DEFICIT (%)</i>	27
<i>TABLE 17 GLOBAL TREATMENT OF ALZHEIMER'S DISEASE, THROUGH 2017 (\$ MILLIONS)</i>	28
<i>FIGURE 5 GLOBAL TREATMENT OF ALZHEIMER'S DISEASE, 2010-2017 (\$ MILLIONS)</i>	28
<i>TABLE 18 GLOBAL POTENTIAL MARKET FOR MEMORY/COGNITION THERAPEUTICS, THROUGH 2017 (\$ MILLIONS)</i>	29
<i>FIGURE 6 GLOBAL MEMORY/COGNITION THERAPEUTICS MARKET BY DISEASE AREA, 2011 (%)</i>	29
KEY PLAYERS	30
<i>TABLE 19 MARKET SHARE OF TOP COMPANIES WORKING IN MEMORY AND COGNITION (%)</i>	30
<i>TABLE 20 MARKETED TREATMENTS FOR ALZHEIMER'S DISEASE</i>	31
DRIVERS	31
ISSUES AND CHALLENGES	31
IMAGING AND DIAGNOSTICS	32

TOPIC	PAGE NO.
Current Use in Alzheimer's Disease	32
Diagnostic Testing Segments	33
Imaging	33
<i>TABLE 21 IMAGING MARKET, 2012 (\$ MILLIONS)</i>	33
<i>FIGURE 7 IMAGING MARKET, 2012 (\$ MILLIONS)</i>	34
Standardization Needed	34
Diagnostics	35
Novel Imaging Agents	36
Opportunities for Biomarkers in AD	36
<i>TABLE 22 BIOMARKERS FOR ALZHEIMER'S DISEASE</i>	37
<i>TABLE 23 GLOBAL MARKET FOR BIOMARKERS IN CLINICAL TRIALS, THROUGH 2017 (\$ MILLIONS)</i>	38
<i>FIGURE 8 GLOBAL MARKET FOR BIOMARKERS IN CLINICAL TRIALS, 2011-2017 (\$ MILLIONS)</i>	39
Testing Hypotheses	41
DIAGNOSTIC TESTS	41
KEY PLAYERS	42
AGILENT TECHNOLOGIES	42
BIOSCAN	43
CAPINTEC INC.	43
DIGIRAD CORPORATION	43
GAMMA MEDICA-IDEAS	43
GE HEALTHCARE	44
HITACHI MEDICAL SYSTEMS AMERICA INC.	44
NYMOX	44
OPTOSONICS INC.	45
PHILIPS HEALTHCARE	45
POSITRON CORP.	46
SIEMENS HEALTHCARE	46
SPECTRUM DYNAMICS LTD.	46
TOSHIBA MEDICAL SYSTEMS	47
ULTRASPECT LTD.	47
VISEN MEDICAL INC.	47
ZECOTEK IMAGING SYSTEMS	48
DRIVERS	48
ISSUES AND CHALLENGES	48
SWOT ANALYSIS	49
<i>TABLE 24 SWOT ANALYSIS OF EXISTING ALZHEIMER'S DISEASE MARKET AND PLAYERS</i>	49
CHAPTER 4 TECHNOLOGIES AND APPLICATIONS	51
COMMON MECHANISMS OF ACTION	51
CHOLINESTERASE INHIBITORS	51
<i>TABLE 25 CHOLINESTERASE INHIBITORS</i>	52
<i>TABLE 26 PRODUCT SIDE EFFECT COMPARISON (%)</i>	53
<i>FIGURE 9 PRODUCT SIDE EFFECT COMPARISON (%)</i>	53
<i>TABLE 27 VACCINES</i>	54
<i>TABLE 28 ANTI-OXIDANTS</i>	54

TOPIC	PAGE NO.
NMDA ANTAGONISTS	54
<i>TABLE 29 NMDA ANTAGONISTS</i>	54
NICOTINICS	55
<i>TABLE 30 NICOTINIC ACETYLCHOLINE ANTAGONISTS</i>	55
CALCINEURINS	55
<i>TABLE 31 CALCINEURINS</i>	56
GABA MODULATORS	56
<i>TABLE 32 ANTI-EPILEPTIC/GABA MODULATORS</i>	56
HORMONES	57
<i>TABLE 33 HORMONES</i>	57
OTHER THERAPEUTIC MECHANISMS	57
<i>TABLE 34 OTC TREATMENTS/NATURAL PRODUCTS</i>	58
IMAGING AND DIAGNOSTICS: MODALITIES AND APPLICATIONS	58
NUCLEAR MEDICINE	59
POSITRON EMISSION TOMOGRAPHY (PET)	60
SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY (SPECT)	61
GAMMA CAMERAS	61
CT (COMPUTED TOMOGRAPHY)	61
DEXA	61
MRI (MAGNETIC RESONANCE IMAGING)	62
ULTRASOUND	63
X-RAY	63
FUSION IMAGING	64
PET/CT	64
SPECT-CT	65
SPECT-CT in Cardiology	65
SPECT-CT in General Nuclear Medicine	66
SPECT-CT in Neurology	66
DIAGNOSTIC IMAGING IN ALZHEIMER'S	66
DISEASE-MODIFYING VS. TREATMENT OF SYMPTOMS	66
SYMPTOMATIC RELIEF-LIFE-CYCLE MANAGEMENT OF EXISTING PRODUCTS	67
OTHER DRUGS TARGETING SYMPTOMATIC RELIEF	67
DRUG RE-PURPOSING	68
GENERICS	68
CHAPTER 5 WORLDWIDE INDUSTRY STRUCTURE	70
GROWTH DRIVERS	70
AGING POPULATION	70
OFF-LABEL USE	70
UNDERSTANDING OF MECHANISMS	71
TRANSCRANIAL MAGNETIC STIMULATION	72
GENETIC MODIFICATIONS	72
GROWTH OBSTACLES	72
UNDERSTANDING OF MECHANISM	73
<i>TABLE 35 CLINICAL SUCCESS RATES BY THERAPEUTIC AREA (%)</i>	73
CO-MORBID DISEASE STATES	73
KEY COMPETITIVE FACTORS	73

TOPIC	PAGE NO.
PRODUCT LAUNCH	74
LIFE CYCLE MANAGEMENT	74
PAYERS	74
INTERNATIONAL ASPECTS	75
<i>TABLE 36 PERCAPITA GOVERNMENT EXPENDITURE ON HEALTHCARE BY COUNTRY, THROUGH 2010 (\$ MILLIONS)</i>	76
CHAPTER 6 LEGISLATION AND REGULATORY ENVIRONMENT	79
VALIDATED TARGETS	79
LACK OF BIOMARKERS	79
TRANSLATIONAL MEDICINE	80
REIMBURSEMENT	80
CHAPTER 7 RELATED DEALS AND PARTNERSHIPS	83
APPROACH	83
DIAGNOSTICS DEALS	83
OVERALL ACTIVITY	84
<i>TABLE 37 DEALS AND PARTNERSHIPS, 2005-2012</i>	84
CHAPTER 8 PIPELINE	88
<i>TABLE 38 DEVELOPMENT PIPELINE OF ALZHEIMER'S DRUGS, BY PHASE</i>	89
<i>FIGURE 10 DEVELOPMENT PIPELINE OF ALZHEIMER'S DRUGS: NUMBER OF PROGRAMS AT EACH CLINICAL PHASE</i>	95
CHAPTER 9 TRENDS AND CHALLENGES	98
AWARENESS OF ALZHEIMER'S	98
DISEASE PATHWAYS BEING ELUCIDATED	98
MANY PROGRAMS IN DEVELOPMENT	98
<i>TABLE 39 SOME NOT-FOR-PROFIT ORGANIZATIONS AND CONSORTIA IN THE AD AREA</i>	99
<i>TABLE 40 INVESTMENT IN ALZHEIMER'S DISEASE COMPANIES, 2008-2012</i>	101
CHAPTER 10 OUTLOOK	104
A VARIETY OF APPROACHES IN RESEARCH	104
MANY PROGRAMS IN DEVELOPMENT	105
CHAPTER 11 PATENT ANALYSIS	107
<i>TABLE 41 KEY PATENT EXPIRY: ALZHEIMER'S THERAPEUTICS, BY CATEGORY THERAPEUTICS AND TECHNOLOGIES</i>	107
<i>TABLE 42 MAJOR U.S. PATENT HOLDERS/FILERS IN ALZHEIMER'S</i>	108
<i>TABLE 43 PATENTS ISSUED, 2011-2012</i>	108
<i>TABLE 44 PATENT APPLICATIONS</i>	128
CHAPTER 12 COMPANY PROFILES	149
ABBOTT LABORATORIES	149
ABLYNX	149
ACCERA, INC.	149
ACUMEN PHARMACEUTICALS	152

TOPIC	PAGE NO.
ADAMAS PHARMACEUTICALS	152
AFFIRIS AG	153
AFFITECH AS	153
ALLON THERAPEUTICS (FKA NEURODISCOVERY)	154
ALZHYME PTY	154
ASTELLAS	154
ASTRAZENECA	155
ATHENA DIAGNOSTICS (THERMO FISHER)	155
AVERA PHARMACEUTICALS	156
BAXTER INTERNATIONAL INC. (BAXTER)	156
BAYER HEALTHCARE PHARMA	157
BELLUS HEALTH	157
BIOFUTURA	158
BIOMERIEUX	158
BIOVAIL	158
BOEHRINGER INGELHEIM	159
BRACCO	159
BRAINCELLS, INC.	159
BRISTOL MYERS SQUIBB	159
CELLZOME	160
CEREGENE	160
COGNITION PHARMACEUTICALS LLC	160
COGNITION THERAPEUTICS	161
COLUCID PHARMACEUTICALS	161
COMENTIS	161
CORTEX PHARMACEUTICALS	162
C2N DIAGNOSTICS	162
CYTOS BIOTECHNOLOGY	162
DAIICHI SANKYO	163
DEBIOPHARM	163
DURECT	163
EISAI	164
ELAN	165
ELI LILLY	165
ENVIVO PHARMACEUTICALS	165
ESTEVE	166
EVOTEC	166
EXONHIT THERAPEUTICS	167
FOREST LABORATORIES	167
GALANTOS PHARMA	168
GALENEA	168
GE HEALTHCARE	168
GLAXOSMITH KLINE	169
HELICON THERAPEUTICS	169
INTELLECT NEUROSCIENCES	169
INTRA-CELLULAR THERAPIES	170
INVERNESS MEDICAL INNOVATIONS	170

TOPIC	PAGE NO.
IPSEN	171
JOHNSON & JOHNSON	171
KEYNEUROTEK	172
LEXICON PHARMACEUTICALS	172
LINK MEDICINE	172
LUNDBECK	173
MEDIVATION	173
MEMORY PHARMACEUTICALS	174
MERCK	174
MERCKSERONO	174
MERZ PHARMA	175
MITHRIDION	175
MITSUBISHI TANABE	175
MORPHOSYS	176
NEUREN PHARMACEUTICALS	176
NEUROPTIX (COGNOPTIX, INC)	177
NEUROSEARCH	177
NEURO-HITECH	178
NEWRON PHARMACEUTICALS	178
NOSCIRA SA	178
NOVARTIS AG	179
NYMOX	179
OLIGOMERIX	180
ORTHO-MCNEIL NEUROLOGICS	180
PFIZER	180
POWER3 MEDICAL PRODUCTS	181
PRANA BIOTECHNOLOGY	182
PROTEOTECH INC.	182
PSYCHOGENICS	182
ROCHE	183
REPROCELL	183
SAMARITAN PHARMACEUTICALS	184
SANOFI-AVENTIS	184
SATORI PHARMACEUTICALS	184
SATORIS	185
SCIELE PHARMA	185
SIEMENS MEDICAL SOLUTIONS	186
SOLVAY	186
SUVEN LIFE SCIENCE	186
TAKEDA	187
TARGACEPT	187
TAURX THERAPEUTICS	187
TAUTATIS	188
TEIKOKU	188
TEVA PHARMACEUTICALS	189
TRANSTECH PHARMA	189
VALEANT PHARMACEUTICALS	190

TOPIC	PAGE NO.
VOYAGER PHARMACEUTICAL / DURAMED	190
WATSON PHARMACEUTICALS	190
WYETH/PFIZER	190

LIST OF TABLES

TABLE HEADING	PAGE NO.
SUMMARY TABLE GLOBAL MARKET FOR ALZHEIMER'S DISEASE, THROUGH 2017 (\$ MILLIONS)	6
TABLE 1 U.S. ALZHEIMER'S PATIENTS, 2002-2050 (MILLIONS)	10
TABLE 2 POPULATION BY SELECTED GEOGRAPHIC REGION, 2011-2050 (MILLIONS)	13
TABLE 3 PERCENT POPULATION OVER 65 BY REGION, 2011 (%)	13
TABLE 4 PEOPLE WITH ALZHEIMER'S DISEASE BY AGE GROUP, 2004-2050 (MILLIONS)	14
TABLE 5 PERCENTAGE OF PEOPLE WITH ALZHEIMER'S, BY AGE BRACKET, 60-94 (%)	14
TABLE 6 GLOBAL DISEASE PREVALENCE: ALZHEIMER'S DISEASE (%)	15
TABLE 7 DIAGNOSTIC TESTS	18
TABLE 8 GLOBAL MARKET FOR ALZHEIMER'S DISEASE BY REGION, THROUGH 2017 (\$ MILLIONS)	23
TABLE 9 EXISTING TREATMENTS FOR ALZHEIMER'S DISEASE	24
TABLE 10 GLOBAL EXISTING MARKET FOR SYMPTOM-ADDRESSING ALZHEIMER'S DISEASE BY TYPE, 2010-2017 (\$ MILLIONS)	25
TABLE 11 ESTIMATED GLOBAL MARKET FOR ALZHEIMER'S DRUG CLASSES BY GEOGRAPHICAL REGION (U.S., EUROPE, JAPAN, OTHERS), 2012 (\$ MILLIONS)	25
TABLE 12 TYPES OF DRUGS USED TO TREAT ALZHEIMER'S DISEASE	26
TABLE 13 MARKET SHARE OF EXISTING THERAPEUTICS FOR ALZHEIMER'S DISEASE, 2011 (%)	26
TABLE 14 BREAKDOWN OF TREATMENT MARKET BY DISEASE SEVERITY (%)	27
TABLE 15 DEMENTIA RATE BY UNDERLYING DISEASE (%)	27
TABLE 16 PERCENT OF PATIENTS WITH DEMENTIA/COGNITIVE DEFICIT (%)	27
TABLE 17 GLOBAL TREATMENT OF ALZHEIMER'S DISEASE, THROUGH 2017 (\$ MILLIONS)	28
TABLE 18 GLOBAL POTENTIAL MARKET FOR MEMORY/COGNITION THERAPEUTICS, THROUGH 2017 (\$ MILLIONS)	29
TABLE 19 MARKET SHARE OF TOP COMPANIES WORKING IN MEMORY AND COGNITION (%)	30
TABLE 20 MARKETED TREATMENTS FOR ALZHEIMER'S DISEASE	31
TABLE 21 IMAGING MARKET, 2012 (\$ MILLIONS)	33
TABLE 22 BIOMARKERS FOR ALZHEIMER'S DISEASE	37
TABLE 23 GLOBAL MARKET FOR BIOMARKERS IN CLINICAL TRIALS, THROUGH 2017 (\$ MILLIONS)	38
TABLE 24 SWOT ANALYSIS OF EXISTING ALZHEIMER'S DISEASE MARKET AND PLAYERS	49
TABLE 25 CHOLINESTERASE INHIBITORS	52
TABLE 26 PRODUCT SIDE EFFECT COMPARISON (%)	53
TABLE 27 VACCINES	54
TABLE 28 ANTI-OXIDANTS	54
TABLE 29 NMDA ANTAGONISTS	54
TABLE 30 NICOTINIC ACETYLCHOLINE ANTAGONISTS	55
TABLE 31 CALCINEURINS	56
TABLE 32 ANTI-EPILEPTIC/GABA MODULATORS	56
TABLE 33 HORMONES	57
TABLE 34 OTC TREATMENTS/NATURAL PRODUCTS	58
TABLE 35 CLINICAL SUCCESS RATES BY THERAPEUTIC AREA (%)	73
TABLE 36 PERCAPITA GOVERNMENT EXPENDITURE ON HEALTHCARE BY COUNTRY, THROUGH 2010 (\$ MILLIONS)	76
TABLE 37 DEALS AND PARTNERSHIPS, 2005-2012	84

TABLE HEADING	PAGE NO.
TABLE 38 DEVELOPMENT PIPELINE OF ALZHEIMER'S DRUGS, BY PHASE	89
TABLE 39 SOME NOT-FOR-PROFIT ORGANIZATIONS AND CONSORTIA IN THE AD AREA	99
TABLE 40 INVESTMENT IN ALZHEIMER'S DISEASE COMPANIES, 2008-2012	101
TABLE 41 KEY PATENT EXPIRY: ALZHEIMER'S THERAPEUTICS, BY CATEGORY THERAPEUTICS AND TECHNOLOGIES	107
TABLE 42 MAJOR U.S. PATENT HOLDERS/FILERS IN ALZHEIMER'S	108
TABLE 43 PATENTS ISSUED, 2011-2012	108
TABLE 44 PATENT APPLICATIONS	128

LIST OF FIGURES

FIGURE TITLE	PAGE NO.
SUMMARY FIGURE GLOBAL MARKET FOR ALZHEIMER'S DISEASE, 2011-2017 (\$ MILLIONS)	7
FIGURE 1 U.S. ALZHEIMER'S PATIENTS, 2002-2050 (MILLIONS)	10
FIGURE 2 PEOPLE WITH ALZHEIMER'S DISEASE BY AGE GROUP 2004-2050	14
FIGURE 3 PERCENTAGE OF PEOPLE WITH ALZHEIMER'S, BY AGE BRACKET, 60-94 (%)	14
FIGURE 4 GLOBAL MARKET FOR ALZHEIMER'S DISEASE, BY REGION, 2011-2017 (\$ MILLIONS)	23
FIGURE 5 GLOBAL TREATMENT OF ALZHEIMER'S DISEASE, 2010-2017 (\$ MILLIONS)	28
FIGURE 6 GLOBAL MEMORY/COGNITION THERAPEUTICS MARKET BY DISEASE AREA, 2011 (%)	29
FIGURE 7 IMAGING MARKET, 2012 (\$ MILLIONS)	34
FIGURE 8 GLOBAL MARKET FOR BIOMARKERS IN CLINICAL TRIALS, 2011-2017 (\$ MILLIONS)	39
FIGURE 9 PRODUCT SIDE EFFECT COMPARISON (%)	53
FIGURE 10 DEVELOPMENT PIPELINE OF ALZHEIMER'S DRUGS: NUMBER OF PROGRAMS AT EACH CLINICAL PHASE	95